Bifonazole--a synopsis of clinical trials worldwide. Status and outlook.
A synopsis is given on the results of 97 clinical trials of efficacy and tolerability involving a total of 3,443 patients in more than 20 countries all over the world. They were carried out with bifonazole cream 1%, solution 1%, gel 1% and powder 1%. 49% of the patients treated suffered from dermatophytosis, 30% from cutaneous candidosis and 21% from pityriasis versicolor. The therapeutic efficacy and the tolerability proved good for the indications studied when administered once daily for a treatment period of 2 or 3 weeks.
D000287:Administration, Topical; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002179:Candidiasis, Cutaneous / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003881:Dermatomycoses / Q000188:drug therapy*; D004361:Drug Tolerance; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007391:International Cooperation; D012393:Rosacea / Q000188:drug therapy; D014010:Tinea Versicolor / Q000188:drug therapy
D000935:Antifungal Agents; D007093:Imidazoles; C036596:bifonazole